Compare IMRX & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMRX | EDD |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.1M | 391.9M |
| IPO Year | 2021 | N/A |
| Metric | IMRX | EDD |
|---|---|---|
| Price | $4.93 | $6.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $17.20 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 254.3K |
| Earning Date | 03-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $4.22 |
| 52 Week High | $10.08 | $4.95 |
| Indicator | IMRX | EDD |
|---|---|---|
| Relative Strength Index (RSI) | 47.13 | 77.13 |
| Support Level | $4.86 | $6.06 |
| Resistance Level | $5.15 | $5.94 |
| Average True Range (ATR) | 0.31 | 0.07 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 60.98 | 90.52 |
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.